ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
The Lancet Oncology
◽
10.1016/s1470-2045(14)70240-2
◽
2014
◽
Vol 15
(9)
◽
pp. 975-985
◽
Cited By ~ 110
Author(s):
Karim Fizazi
◽
Christophe Massard
◽
Petri Bono
◽
Robert Jones
◽
Vesa Kataja
◽
...
Keyword(s):
Prostate Cancer
◽
Dose Escalation
◽
Phase 1
◽
Phase 2
◽
Castration Resistant Prostate Cancer
◽
Open Label
◽
Castration Resistant
◽
Open Label Phase
Download Full-text
Related Documents
Cited By
References
Re: Activity and Safety of ODM-201 in Patients with Progressive Metastatic Castration-resistant Prostate Cancer (ARADES): An Open-label Phase 1 Dose-escalation and Randomised Phase 2 Dose Expansion Trial
European Urology
◽
10.1016/j.eururo.2014.11.019
◽
2015
◽
Vol 67
(2)
◽
pp. 348-349
Author(s):
Anders Bjartell
Keyword(s):
Prostate Cancer
◽
Dose Escalation
◽
Phase 1
◽
Phase 2
◽
Castration Resistant Prostate Cancer
◽
Open Label
◽
Castration Resistant
◽
Open Label Phase
Download Full-text
Faculty Opinions recommendation of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.739562946.793583755
◽
2021
◽
Author(s):
Patrick Richard
Keyword(s):
Prostate Cancer
◽
Phase 2
◽
Castration Resistant Prostate Cancer
◽
Open Label
◽
Phase 2 Trial
◽
Castration Resistant
◽
Open Label Phase
Download Full-text
Faculty Opinions recommendation of Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.732320563.793553396
◽
2018
◽
Author(s):
Michael Glode
Keyword(s):
Prostate Cancer
◽
Phase 2
◽
Castration Resistant Prostate Cancer
◽
Open Label
◽
Androgen Therapy
◽
Castration Resistant
◽
Open Label Phase
Download Full-text
Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases
The Prostate
◽
10.1002/pros.23893
◽
2019
◽
Vol 79
(14)
◽
pp. 1683-1691
◽
Cited By ~ 2
Author(s):
Oliver Sartor
◽
Daniel Heinrich
◽
Neil Mariados
◽
Maria José Méndez Vidal
◽
Daniel Keizman
◽
...
Keyword(s):
Prostate Cancer
◽
Bone Metastases
◽
Phase 1
◽
Castration Resistant Prostate Cancer
◽
Open Label
◽
Castration Resistant
◽
Radium 223
◽
Open Label Phase
Download Full-text
An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
International Journal of Clinical Oncology
◽
10.1007/s10147-019-01526-7
◽
2019
◽
Vol 24
(12)
◽
pp. 1596-1604
◽
Cited By ~ 1
Author(s):
Tomohiro Tsuchiya
◽
Keiichiro Imanaka
◽
Yuki Iwaki
◽
Ryo Oyama
◽
Katsuyoshi Hashine
◽
...
Keyword(s):
Prostate Cancer
◽
Androgen Receptor
◽
Phase 1
◽
Japanese Patients
◽
Castration Resistant Prostate Cancer
◽
Open Label
◽
Phase 1 Study
◽
Androgen Receptor Antagonist
◽
Castration Resistant
◽
Open Label Phase
Download Full-text
Radium-223 re-treatment in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up from an international, open-label, phase 1/2 study
European Urology Supplements
◽
10.1016/s1569-9056(18)31441-6
◽
2018
◽
Vol 17
(2)
◽
pp. e872-e873
Author(s):
D. Heinrich
◽
L. Nordquist
◽
N. Mariados
◽
M.J. Méndez Vidal
◽
D. Keizman
◽
...
Keyword(s):
Prostate Cancer
◽
Bone Metastases
◽
Phase 1
◽
Castration Resistant Prostate Cancer
◽
Open Label
◽
Castration Resistant
◽
Radium 223
◽
Open Label Phase
Download Full-text
Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study
European Urology
◽
10.1016/j.eururo.2015.09.046
◽
2016
◽
Vol 69
(5)
◽
pp. 834-840
◽
Cited By ~ 26
Author(s):
Christophe Massard
◽
Heidi M. Penttinen
◽
Egils Vjaters
◽
Petri Bono
◽
Vilnis Lietuvietis
◽
...
Keyword(s):
Prostate Cancer
◽
Antitumor Activity
◽
Phase 1
◽
Castration Resistant Prostate Cancer
◽
Open Label
◽
Phase 1 Study
◽
Castration Resistant
◽
Open Label Phase
Download Full-text
Open-label, phase I, dose escalation study to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E (GEN0101) in castration-resistant prostate cancer patients
European Urology Supplements
◽
10.1016/s1569-9056(19)30876-0
◽
2019
◽
Vol 18
(1)
◽
pp. e1220
Author(s):
K. Fujita
◽
Y. Nakai
◽
D. Kato
◽
A. Kawashima
◽
T. Ujike
◽
...
Keyword(s):
Prostate Cancer
◽
Phase I
◽
Cancer Patients
◽
Dose Escalation
◽
Castration Resistant Prostate Cancer
◽
Open Label
◽
Dose Escalation Study
◽
Safety And Efficacy
◽
Castration Resistant
◽
Open Label Phase
Download Full-text
Radium-223 re-treatment in an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up.
Journal of Clinical Oncology
◽
10.1200/jco.2018.36.15_suppl.5022
◽
2018
◽
Vol 36
(15_suppl)
◽
pp. 5022-5022
Author(s):
A. Oliver Sartor
◽
Daniel Heinrich
◽
Neil Mariados
◽
María José Méndez-Vidal
◽
Daniel Keizman
◽
...
Keyword(s):
Prostate Cancer
◽
Bone Metastases
◽
Phase 1
◽
Castration Resistant Prostate Cancer
◽
Open Label
◽
Castration Resistant
◽
Radium 223
◽
Open Label Phase
Download Full-text
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
The Lancet Oncology
◽
10.1016/s1470-2045(21)00376-4
◽
2021
◽
Author(s):
Johann S de Bono
◽
Niven Mehra
◽
Giorgio V Scagliotti
◽
Elena Castro
◽
Tanya Dorff
◽
...
Keyword(s):
Prostate Cancer
◽
Dna Repair
◽
Phase 2
◽
Castration Resistant Prostate Cancer
◽
Open Label
◽
Phase 2 Trial
◽
Castration Resistant
◽
Open Label Phase
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close